The Screen · Healthcare · Medical Instruments & Supplies
AptarGroup, Inc.
ATR · the NYSE · USD · Market cap $7.8B · 14,000 employees
AptarGroup, Inc.
Not yet scored
123.05 USD
At the last full screen 2026-09-10
Screened 2026-09-10 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
AptarGroup, Inc. holds its Markdown at $123.05. The statistical read favours the sellers, held for 26 days.
As held on the ledger · 2026-09-10
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 26 days
Price at the screen
$123.05
Valuation
22.21 trailing · 19.48 forward price to earnings
Values screen
Not scored· score 70.0
Beta
0.38
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 12.4% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus None. The average target sits +33% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pumps and dispensers come at a premium price
Every time a patient uses an inhaler or someone spritzes perfume, AptarGroup supplies the mechanism behind it. Revenue grows at 11% with a 10% profit margin and 15% ROE, and the ethical screen clears without issue. Yet the shares sit 3% above our fair value, leaving no margin of safety and a clear pass.
The forward multiple of 21.2 times earnings already prices in solid growth. Analyst targets at 160 do not alter the simple fact that current levels leave nothing on the table for new buyers.
Unknown competitive protection adds further uncertainty around sustained returns. Paying up in a steady sector rarely ends well when assumptions shift. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ATR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup · changed$135.78+2.4%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (7 analysts) rates it none, with a mean price target of $163.
2026-07-22Distribution$132.61+12.6%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 12.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (7 analysts) rates it none, with a mean price target of $163.
2026-07-18Distribution$117.72+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (7 analysts) rates it none, with a mean price target of $163.
2026-07-03Distribution$117.72+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$117.72Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.